Comparative Pharmacology
Head-to-head clinical analysis: NEO FRADIN versus NITROFURANTOIN MONOHYDRATE MACROCRYSTALS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO FRADIN versus NITROFURANTOIN MONOHYDRATE MACROCRYSTALS.
NEO-FRADIN vs NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial cell wall synthesis, protein synthesis, and DNA/RNA synthesis. It is bacteriostatic at low concentrations and bactericidal at higher concentrations.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
100 mg orally twice daily for 5-7 days; for uncomplicated urinary tract infection.
None Documented
None Documented
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
Terminal elimination half-life: 20-60 minutes (average ~30 min) in patients with normal renal function; prolonged in renal impairment (e.g., CrCl <60 mL/min).
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Renal excretion of unchanged drug accounts for approximately 40% of the dose; tubular reabsorption occurs. Biliary/fecal elimination is minimal (<5%).
Category C
Category D/X
Antibiotic
Antibiotic